Local intraluminal delivery of a smooth muscle-targeted RNA ligand inhibits neointima growth in a porcine model of peripheral vascular disease

Anti-proliferative agents have been the primary therapeutic drug of choice to inhibit restenosis after endovascular treatment. However, recent safety and efficacy concerns for patients who underwent peripheral artery disease revascularization have demonstrated the need for alternative therapeutics....

Descripción completa

Detalles Bibliográficos
Autores principales: Yazdani, Saami K., Lei, Beilei, Cawthon, Claire V., Cooper, Kathryn, Huett, Clifton, Giangrande, Paloma H., Miller, Francis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403884/
https://www.ncbi.nlm.nih.gov/pubmed/36090749
http://dx.doi.org/10.1016/j.omtn.2022.08.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403884/
https://www.ncbi.nlm.nih.gov/pubmed/36090749
http://dx.doi.org/10.1016/j.omtn.2022.08.007

Ejemplares similares